Tyra biosciences initiates surf301 phase 1/2 clinical study and doses first patient with tyra-300

-tyra-300 is the first oral, fgfr3-selective agent to be evaluated in the clinic- -conference call and webcast today, nov. 29th, at 9:00 am et- carlsbad, calif. , nov. 29, 2022 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the initiation of its surf301 phase 1/2 clinical study, with first patient dosed with tyra-300.
TYRA Ratings Summary
TYRA Quant Ranking